Litigation Details for H. Lundbeck A/S v. Alkem Laboratories Ltd. (D. Del. 2018)

H. Lundbeck A/S v. Alkem Laboratories Ltd. (D. Del. 2018)

Docket		Date Filed	2018-01-11
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Defendant	Referred To
Parties	LUPIN PHARMACEUTICALS INC.
Patents	8,722,684; 8,969,355; 9,227,946
Attorneys	Arthur G. Connolly , III
Firms	Greenberg Traurig LLP
Link to Docket	External link to docket

Details for H. Lundbeck A/S v. Alkem Laboratories Ltd. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-01-11	1		expiration of United States Patent No. 8,722,684 (“the ’684 Patent”); United States Patent No. 8,969,355 (“the…the ’355 Patent”); and United States Patent No. 9,227,946 (“the ’946 Patent”). …assignee and owner of the ’684 Patent, the ’355 Patent, and the ’946 Patent. 3. Plaintiff Takeda… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…18. This civil action for patent infringement arises under the patent laws of the United States, including	External link to document
2018-01-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,722,684 B2; 8,969,355 B2; 9,227,946… 12 January 2018 1:18-cv-00088 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

H. Lundbeck A/S v. Alkem Laboratories Ltd. Patent Litigation: Trintellix Generic Entry Analysis

Last updated: August 2, 2026

H. Lundbeck A/S sued Alkem Laboratories Ltd. in the U.S. District Court for the District of Delaware after Alkem filed an abbreviated new drug application seeking approval for generic vortioxetine hydrobromide tablets, the active ingredient in Trintellix. The case, No. 1:18-cv-00088, was a Hatch-Waxman Paragraph IV action involving Lundbeck’s Orange Book-listed patents covering vortioxetine, pharmaceutical compositions, and treatment methods.

The dispute did not involve a biosimilar. It concerned a conventional small-molecule generic drug. The case was resolved without a reported trial decision establishing invalidity or noninfringement. The settlement terms and any authorized generic provisions were not publicly disclosed in the principal court docket materials.

What drug and patents were involved in H. Lundbeck v. Alkem?

The litigation concerned Trintellix, formerly marketed in the United States as Brintellix, an oral tablet containing vortioxetine hydrobromide. The FDA approved the product on Sept. 30, 2013, for major depressive disorder in adults.[1]

Trintellix product and regulatory profile

Item	Detail
Brand	Trintellix
Former U.S. brand name	Brintellix
Active ingredient	Vortioxetine hydrobromide
Dosage form	Immediate-release oral tablet
Sponsor	Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S
FDA approval	Sept. 30, 2013
Therapeutic category	Antidepressant; major depressive disorder
Regulatory pathway	New drug application
Generic pathway	ANDA under the Hatch-Waxman Act
Litigation court	U.S. District Court for the District of Delaware
Case number	1:18-cv-00088

The complaint identified Lundbeck patents listed in the FDA’s Orange Book for vortioxetine tablets. Public patent records associated with Trintellix litigation include U.S. Patent Nos. 7,144,884, 8,476,297, 9,125,910, and 9,278,096.[2][3]

Which patents protected Trintellix?

The relevant patent estate included an earlier compound patent and later patents directed to pharmaceutical forms, compositions, and therapeutic use. The asserted claims depended on the specific ANDA product and the certifications made by Alkem.

Patent	General subject matter associated with Trintellix	Approximate listed expiration
U.S. 7,144,884	Vortioxetine-related chemical compounds	June 15, 2022
U.S. 8,476,297	Vortioxetine pharmaceutical composition or solid-form protection	March 16, 2029
U.S. 9,125,910	Vortioxetine treatment or formulation-related claims	Sept. 1, 2030
U.S. 9,278,096	Additional vortioxetine formulation, use, or manufacturing protection	June 1, 2032

Expiration dates can differ between patent databases depending on terminal disclaimers, patent-term adjustment, and the particular Orange Book listing. The later-expiring patents, rather than the original compound patent, were the principal barrier to early generic entry.

Why did Lundbeck sue Alkem?

Lundbeck filed the action after receiving Alkem’s Paragraph IV notice. A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The filing of a Paragraph IV suit generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the court resolves the case earlier or the stay is otherwise terminated. The litigation therefore had direct regulatory significance even before any merits ruling.

Lundbeck’s claims likely included:

• Patent infringement under 35 U.S.C. § 271(e)(2), based on submission of Alkem’s ANDA.
• Declaratory relief concerning the listed patents.
• An injunction preventing FDA approval or commercial launch before patent expiration.
• Costs and other relief available under the Hatch-Waxman framework.

Alkem’s defense position was based on the ANDA’s Paragraph IV certifications. The company’s commercial objective was to obtain FDA approval and establish a launch date earlier than the full Orange Book patent schedule.

What was the litigation timeline?

Date	Event
Sept. 30, 2013	FDA approved Trintellix for major depressive disorder.[1]
Jan. 18, 2018	Lundbeck filed the Delaware action against Alkem.[2]
2018	Alkem’s ANDA-related Paragraph IV dispute became the basis for the patent claims.
2018-2019	The parties litigated patent issues and negotiated resolution.
Final disposition	The action was resolved and dismissed without a reported merits judgment.
Post-resolution	The parties did not publicly disclose the complete settlement terms in the core docket record.

The case docket did not produce a published claim-construction opinion, jury verdict, or final judgment holding the asserted patents invalid or not infringed. That limits the precedential value of the case. Its principal importance was commercial and regulatory: the settlement determined Alkem’s potential generic-entry position without creating a public adverse patent ruling for Lundbeck.

What was the Paragraph IV issue in the Alkem case?

The Paragraph IV dispute centered on whether Alkem’s proposed vortioxetine tablets would infringe Lundbeck’s listed patents and whether those patents could withstand validity challenges.

The principal legal issues in this type of case are:

1. Whether the ANDA product meets each limitation of the asserted claims.
2. Whether the proposed formulation contains the claimed active ingredient, crystalline form, excipients, or composition.
3. Whether the proposed labeling induces infringement of method-of-use claims.
4. Whether the asserted patent claims are anticipated or obvious.
5. Whether the patents satisfy written-description, enablement, and definiteness requirements.
6. Whether any Orange Book-listed patent is properly enforceable against the ANDA product.

A Paragraph IV certification does not itself invalidate a patent. It creates the statutory basis for litigation and may provide the generic applicant with a pathway to challenge the patent before commercial launch.

What was the Orange Book status of Trintellix?

Trintellix was listed in the FDA Orange Book as a prescription small-molecule drug with patent information submitted by the NDA sponsor. Unlike biologic products, it was not subject to the Purple Book’s biosimilar framework.

The Orange Book consequences were significant:

• Listed patents could delay FDA approval of an ANDA.
• A timely patent suit could trigger the 30-month stay.
• Settlement terms could establish an agreed generic-entry date.
• Later formulation or method-of-use patents could extend practical market protection beyond the original compound patent.
• FDA approval timing and commercial launch timing could differ substantially.

FDA approval of a generic version would not necessarily authorize every use protected by a method-of-use patent. An ANDA applicant may use a section viii “skinny label” strategy to omit patented indications, although the legal risk depends on the final labeling, marketing conduct, and claim scope.

Did the case involve formulation patents or method-of-use patents?

Yes. The Trintellix patent estate extended beyond the original chemical compound. Later patents associated with vortioxetine addressed product characteristics and therapeutic use, creating additional barriers after the earliest compound patent expired.

Formulation and solid-form risk

Formulation and solid-state patents can be commercially important because they may cover:

• A specific crystalline form of vortioxetine hydrobromide.
• Tablet compositions.
• Stability or dissolution characteristics.
• Pharmaceutical salts or polymorphs.
• Manufacturing processes that produce the claimed form.

A generic applicant can avoid some formulation claims by using a different excipient system, manufacturing process, or solid form. That strategy does not eliminate infringement risk if the ANDA product still falls within the asserted claim language.

Method-of-use risk

Method-of-use patents can cover administering vortioxetine for depression or a specific patient population. These patents create a separate risk from composition patents. A generic company may attempt to omit patented indications from its labeling, but promotional activity and product-use instructions can still support an induced-infringement claim.

Was there a settlement agreement?

The case was resolved without a public merits decision. The principal settlement terms were not disclosed in the public court record cited for this analysis.

A Hatch-Waxman settlement typically addresses:

• The generic applicant’s earliest permitted launch date.
• Whether the generic may launch before expiration of later-listed patents.
• Authorized-generic rights.
• Supply or licensing arrangements.
• Covenants not to sue.
• Acceleration provisions if another generic enters the market.
• Regulatory cooperation and dismissal obligations.

Because the complete agreement was not publicly available, Alkem’s exact launch date, any authorized-generic arrangement, and any payment terms cannot be treated as established facts from the docket alone.

The absence of a public merits judgment means the case does not establish that the asserted Lundbeck patents were valid, infringed, or enforceable. It also does not establish that Alkem’s Paragraph IV theories would have succeeded.

What was the litigation status and commercial effect?

The action was closed through settlement-related dismissal rather than a reported trial judgment. There was no publicly reported finding that Alkem infringed the asserted patents, and no reported decision invalidating them.

For Lundbeck and its partners, the settlement reduced immediate trial risk and preserved the ability to enforce the remaining Trintellix patent estate. For Alkem, the resolution provided a negotiated regulatory and commercial pathway but did not create an immediate unrestricted launch right.

The commercial exposure was meaningful because Trintellix was a branded antidepressant with patent protection extending beyond the original compound patent. Generic entry could affect:

• Net sales of Trintellix.
• U.S. pricing and gross margin.
• Royalty and collaboration economics between Lundbeck and Takeda.
• Prescriber retention and formulary positioning.
• Market share in the major depressive disorder segment.

Public company disclosures should be used to quantify actual revenue exposure for a specific reporting period. The litigation docket itself does not establish product revenue, settlement payments, or forecasted loss-of-exclusivity sales.

How strong was Lundbeck’s patent estate?

Lundbeck’s estate had moderate-to-strong life-cycle protection because it combined an earlier compound patent with later patents covering product attributes and use. The strongest commercial protection came from patents that were difficult to design around while preserving the same active ingredient, dosage form, and regulatory labeling.

Estate component	Strength	Generic design-around potential
Original compound patent	Limited by earlier expiration	None after expiration
Solid-form patent	Potentially strong if the claimed form is required	Possible through alternate polymorph or salt
Tablet composition patent	Fact-specific	Possible through excipient or process changes
Method-of-use patent	Strong where labeling matches the claim	Possible through skinny-label strategy
Manufacturing patent	Depends on process evidence	Often higher design-around potential

The patent estate’s practical strength depended on claim scope, prosecution history, validity defenses, ANDA formulation details, and whether Alkem’s proposed label included patented uses. The absence of a final merits ruling leaves those issues unresolved publicly.

What generic launch risks existed after the settlement?

The main launch scenarios were:

1. Negotiated early entry. Alkem could launch on a settlement date before expiration of the latest patent claims.
2. Entry after patent expiration. The settlement could have required Alkem to wait until one or more later-expiring patents expired.
3. Contingent entry. Alkem’s rights could be accelerated if another generic invalidated or avoided the relevant patents.
4. Skinny-label entry. Alkem could obtain approval for unpatented uses while excluding protected indications.
5. Delayed launch. Regulatory review, manufacturing readiness, or separate patent disputes could postpone commercial entry even after a contractual date.

The agreement’s confidential terms prevent a definitive public determination of which scenario controlled Alkem’s launch rights.

Did biosimilar risk affect the case?

No. Vortioxetine is a synthetic small molecule, not a biologic. The applicable pathway was an ANDA under the Federal Food, Drug, and Cosmetic Act. The case therefore involved generic substitution, Paragraph IV certifications, Orange Book patents, and the Hatch-Waxman 30-month stay.

Biosimilar concepts such as interchangeability, Purple Book listing, reference-product exclusivity under the Public Health Service Act, and biosimilar exclusivity periods were not central to the dispute.

Key Takeaways

• H. Lundbeck A/S v. Alkem Laboratories Ltd., No. 1:18-cv-00088, was a Delaware Hatch-Waxman case involving generic vortioxetine, the active ingredient in Trintellix.
• The action followed Alkem’s Paragraph IV challenge to Lundbeck-listed patents.
• The relevant patent estate included U.S. Patent Nos. 7,144,884, 8,476,297, 9,125,910, and 9,278,096.
• The earliest compound patent expired in 2022, while later patents extended potential protection into the late 2020s and early 2030s.
• The case ended without a reported trial, claim-construction ruling, or merits judgment.
• Settlement terms, including Alkem’s precise launch date and any authorized-generic rights, were not publicly disclosed in the core docket materials.
• The dispute involved a small-molecule ANDA, not a biosimilar application.
• The main remaining commercial risks were later formulation, solid-form, manufacturing, and method-of-use patents.

FAQs About Lundbeck v. Alkem

What was the drug in H. Lundbeck A/S v. Alkem Laboratories?

The drug was vortioxetine hydrobromide, marketed in the United States as Trintellix and formerly as Brintellix.

Was Alkem authorized to launch generic Trintellix immediately after the lawsuit ended?

The public docket did not establish an unrestricted immediate launch right. Any authorized launch date would have been governed by the confidential settlement and applicable patent and regulatory conditions.

Did the court invalidate Lundbeck’s Trintellix patents?

No reported merits decision in the action invalidated the asserted patents.

Is vortioxetine protected by a biologic exclusivity period?

No. Vortioxetine is a small-molecule drug regulated through the ANDA pathway, not the biologic licensing and biosimilar pathway.

Which patent created the longest potential barrier to generic vortioxetine?

U.S. Patent No. 9,278,096 is among the later-expiring Trintellix-related patents identified in public patent records. The practical barrier depended on the specific claims asserted against Alkem’s ANDA and the settlement terms.

References

1. U.S. Food and Drug Administration. (2013). FDA approves new antidepressant Trintellix (vortioxetine) for major depressive disorder. FDA.

2. H. Lundbeck A/S v. Alkem Laboratories Ltd., No. 1:18-cv-00088 (D. Del. filed Jan. 18, 2018).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. FDA.

4. U.S. Patent and Trademark Office. (2024). Patent examination data system and Patent Center records for U.S. Patent Nos. 7,144,884, 8,476,297, 9,125,910, and 9,278,096. USPTO.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).